PMC

Enrollment, screening results and outcomes of hrHPV positive in 1916 subjects. CIN, cervical intraepithelial neoplasia; CC, cervical cancer. a. HPV16+ includes HPV16+, with or without HPV18+, and with or without other HR‐HPV+; b. HPV18+ includes HPV16−, HPV18+, and with or without other HR‐HPV+; c. Other HR‐HPV+ include HPV16−, and HPV18−, and other HR‐HPV+

Receiver operating characteristic (ROC) curves. (A) Cut‐off point for predicting CIN2+ is 34.80 (area under the ROC curve, 0.653); (B) Cut‐off value of 46.00 predicts CIN3+ (area under the ROC curve, 0.691)

Distribution of HR‐HPV genotypes in high grade cervical lesions. HR‐HPV, high‐risk human papillomavirus; HR‐HPV genotypes were detected using the HPV GenoArray test kit. CIN 2+, cervical intraepithelial neoplasia grade 2 or worse; CIN 3+, cervical intraepithelial neoplasia grade 3 or worse

Distribution of HPV16/HPV18 infection according to cervical lesions and different age groups. (A) The distribution of HPV16 infection; (B) The distribution of HPV18 infection. Figure 4 Receiver operating characteristic (ROC) curves. (A) Cut‐off point for predicting CIN2+ is 34.80 (area under the ROC curve, 0.653); (B) Cut‐off value of 46.00 predicts CIN3+ (area under the ROC curve, 0.691)